Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its ...

Various studies have pointed toward GLP-1 RAs causing mental health complications, such as anxiety and depression. The National Institutes of Health (NIH) published research in June 2024 that ...

The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...

Zahid’s case is not an exception. It’s the shape of a crisis that’s spreading rapidly and silently across Pakistan. Health ...

Could the same medication that causes people to lose weight hold the key to reducing drinking? In a new paper at the European ...

First-generation GLP-1 weight-loss drugs can help reduce the risk of obesity-related cancers, new research shows. Liraglutide ...

To investigate whether Liraglutide had a neuroprotective after cardiac arrest and return of spontaneous circulation (CA/ROSC) and explore its potential mechanisms. Adopting an 8-min asphyxial cardiac ...

GLP-1s may help reduce alcohol intake among adults with overweight or obesity, according to data presented at the European ...

Medications like semaglutide and liraglutide may help to reduce the risk of heart attacks, strokes, and other major adverse ...

Learn how GLP-1 receptor agonists show promise in reducing alcohol consumption and aiding weight loss in obesity treatment.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in ...

New research presented at the European Congress on Obesity (ECO 2025) and published in the journal Diabetes, Obesity and ...